Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop
Journal
Antiviral Research
Journal Volume
150
Pages
93-100
Date Issued
2018
Author(s)
Block T.M.
Alter H.
Brown N.
Brownstein A.
Brosgart C.
Chang K.-M.
Cohen C.
El-Serag H.
Feld J.
Gish R.
Glenn J.
Greten T.F.
Guo J.-T.
Hoshida Y.
Kowdley K.V.
Li W.
Lok A.S.
McMahon B.
Mehta A.
Perrillo R.
Rice C.M.
Rinaudo J.
Schinazi R.F.
Shetty K.
Abstract
In early 2017, the Hepatitis B Foundation invited 30 experts in the fields of hepatitis B and liver cancer research to identify projects they deemed important to the goal of finding a cure for chronic hepatitis B and D and the diseases with which these viral infections are associated. They were also asked to identify general categories of research and to prioritize sub-project topics within those areas. The experts generally agreed on broadly defined areas of research, but there was usually little difference between the highest and lowest scoring projects; for the most part, all programs described in this document were considered valuable and necessary. An executive summary of this discussion was recently published (Alter et al., Hepatology 2017). The present manuscript reports the areas of research identified by the workshop participants, provides a brief rationale for their selection, and attempts to express differences among the priorities assigned to each area of research, when such distinctions were expressed. ? 2017 Baruch S. Blumberg Institute
Subjects
Antiviral therapy; Hepatitis B; Hepatitis D; Hepatocellular carcinoma
SDGs
Other Subjects
antivirus agent; entecavir; hepatitis B antigen; hepatitis B virus X protein; hepatitis B(e) antigen; hepatitis Bc antigen; host factor; lamivudine; nucleotidyltransferase inhibitor; ribonuclease H; tenofovir; unclassified drug; virus DNA; antivirus agent; adaptive immunity; antiviral therapy; chronic hepatitis B; Conference Paper; delta agent hepatitis; human; innate immunity; liver cell carcinoma; liver cirrhosis; nonhuman; priority journal; virology; chronic hepatitis B; drug effect; Hepatitis B virus; research; virology; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Research
Publisher
Elsevier B.V.
Type
conference paper